CO4480098A1 - Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . - Google Patents
Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario .Info
- Publication number
- CO4480098A1 CO4480098A1 CO96066993A CO96066993A CO4480098A1 CO 4480098 A1 CO4480098 A1 CO 4480098A1 CO 96066993 A CO96066993 A CO 96066993A CO 96066993 A CO96066993 A CO 96066993A CO 4480098 A1 CO4480098 A1 CO 4480098A1
- Authority
- CO
- Colombia
- Prior art keywords
- conforming
- complementary solvent
- danofloxacin
- complementary
- solvent
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 5
- 239000002904 solvent Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 title abstract 2
- 229960004385 danofloxacin Drugs 0.000 title abstract 2
- 150000003752 zinc compounds Chemical class 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000007924 injection Substances 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 150000002681 magnesium compounds Chemical class 0.000 abstract 1
- 239000003186 pharmaceutical solution Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical group [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SOLUCIONES FARMACEUTICAS ACUOSAS ADECUADAS PARA INYECCION EN UN HUESPED, QUE TIENEN MEJORADA LA TOLERANCIA EN EL SITIO DE LA INYECCION, COMPRENDEN DANOFLOXACINA O SUS SALES FARMACEUTICAMENTE ACEP- TABLES Y UN COMPUESTO DE MAGNESIO O DE CINC. EL COMPUESTO DE CINC REQUIERE ADEMAS LA PRESENCIA DE UN DISOLVENTE COMPLEMENTARIO. ADECUADA EN UN HUESPED, QUE COMPRENDE DANOFLOXACI- NA O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES EN UNA CANTIDAD SUFICIENTE PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS Y, (1) UN COMPUESTO DE MAGNESIO O, (2) UN COMPUESTO DE CINC MEZCLADO CON UN DISOLVENTE COMPLEMENTARIO, ESTANDO PRESENTES DICHOS COMPUESTOS Y DICHO DISOLVENTE COMPLEMENTA- RIO EN CANTIDADES QUE SON SUFICIENTES PARA MEJORAR LA TOLERANCIA EN EL SITIO DE LA INYECCION. UNA CONFORME A LA REIVINDICACION 1, EN LA QUE DI- CHO COMPUESTO DE MAGNESIO ESTA PRESENTE JUNTO CON UN DISOLVENTE COMPLEMENTARIO. UNA CONFORME A LA REIVINDICACION 1 O 2, EN LA QUE DICHO DISOLVENTE COMPLEMENTARIO ES AL MENOS UNO DE 2-PIRROLIDONA, PROPILENGLICOL, POLIETILENGLICOL Y N-METIL PIRROLIDONA, CADA UNO DE ELLOS OPCIONAL- MENTE JUNTO CON POLIVINILPIRROLIDONA. UNA CONFORME A UNA CUALQUIERA DE LAS REIVINDICA- CIONES 1, 2 O 3, EN LA QUE DICHA SOLUCION CONTIENE ADEMAS UN ANTIOXIDANTE. UNA CONFORME A LA REIVINDICACION 4, EN LA QUE DI- CHO ANTIOXIDANTE ES FORMALDEHIDO SULFOXILATO SODI- CO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US905295P | 1995-12-21 | 1995-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4480098A1 true CO4480098A1 (es) | 1997-07-09 |
Family
ID=21735307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO96066993A CO4480098A1 (es) | 1995-12-21 | 1996-12-20 | Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US5811130A (es) |
| EP (1) | EP0868183B1 (es) |
| JP (1) | JP3416145B2 (es) |
| KR (1) | KR100402570B1 (es) |
| CN (1) | CN1104899C (es) |
| AP (1) | AP706A (es) |
| AR (1) | AR005147A1 (es) |
| AT (1) | ATE212551T1 (es) |
| AU (1) | AU709474B2 (es) |
| BG (1) | BG63933B1 (es) |
| BR (1) | BR9612230A (es) |
| CA (1) | CA2239352C (es) |
| CO (1) | CO4480098A1 (es) |
| CZ (1) | CZ293747B6 (es) |
| DE (1) | DE69618987T2 (es) |
| DK (1) | DK0868183T3 (es) |
| DZ (1) | DZ2146A1 (es) |
| EG (1) | EG24071A (es) |
| ES (1) | ES2167609T3 (es) |
| GT (1) | GT199600098A (es) |
| HR (1) | HRP960607B1 (es) |
| HU (1) | HU227918B1 (es) |
| IL (1) | IL124454A (es) |
| IS (1) | IS2010B (es) |
| MA (1) | MA24035A1 (es) |
| MX (1) | MX9805026A (es) |
| MY (1) | MY117109A (es) |
| NO (1) | NO315734B1 (es) |
| NZ (2) | NZ320545A (es) |
| OA (1) | OA10697A (es) |
| PE (1) | PE25798A1 (es) |
| PL (1) | PL186795B1 (es) |
| PT (1) | PT868183E (es) |
| RS (1) | RS49523B (es) |
| RU (1) | RU2141827C1 (es) |
| SI (1) | SI0868183T1 (es) |
| SK (1) | SK284412B6 (es) |
| TN (1) | TNSN96163A1 (es) |
| TW (1) | TW449475B (es) |
| UA (1) | UA56151C2 (es) |
| WO (1) | WO1997023217A1 (es) |
| ZA (1) | ZA9610780B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID21415A (id) * | 1997-12-05 | 1999-06-10 | Upjohn Co | Senyawa-senyawa antibiotik magnesium quinolon |
| US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
| DE19937115A1 (de) | 1999-08-06 | 2001-02-08 | Bayer Ag | Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon |
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| US20030153585A1 (en) * | 2000-01-13 | 2003-08-14 | Sven-Alexander Schreder | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
| CA2680475A1 (en) * | 2000-12-28 | 2002-07-11 | Shigeyuki Takada | Sustained-release preparation |
| JP2005535644A (ja) * | 2002-06-26 | 2005-11-24 | ファルマシア コーポレイション | 安定な非経口パレコキシブ液体製剤 |
| EP1764102A4 (en) * | 2004-07-02 | 2010-08-25 | Daiichi Seiyaku Co | MEDICINAL COMPOSITION CONTAINING QUINOLONE |
| PL2594272T3 (pl) * | 2005-05-18 | 2018-11-30 | Horizon Orphan Llc | Fluorochinolony w aerozolu i ich zastosowania |
| US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| FR2896416B1 (fr) | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
| LT1991201T (lt) * | 2006-02-10 | 2018-07-25 | Pari Pharma Gmbh | Puškiami antibiotikai inhaliaciniam gydymui |
| US20070197548A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone compositions |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| WO2010042549A1 (en) | 2008-10-07 | 2010-04-15 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| WO2010042553A1 (en) | 2008-10-07 | 2010-04-15 | Mpex Pharmaceuticals, Inc. | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| JP6180012B2 (ja) | 2009-09-04 | 2017-08-16 | ラプター ファーマスーティカルズ，インコーポレイテッド | 嚢胞性線維症を治療するためのエアロゾル化レボフロキサシンの使用 |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| US10406149B2 (en) | 2015-06-02 | 2019-09-10 | Kyorin Pharmaceutical Co., Ltd. | Aqueous liquid formulation |
| WO2016195014A1 (ja) | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| JP6675396B2 (ja) | 2015-06-02 | 2020-04-01 | 杏林製薬株式会社 | 水性液剤 |
| CN110248643B (zh) * | 2017-02-13 | 2023-11-24 | 拜耳动物保健有限责任公司 | 含普拉沙星的液体组合物 |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523505A (en) * | 1894-07-24 | Island | ||
| DE3517709A1 (de) * | 1985-01-05 | 1986-07-10 | Bayer Ag | Basische zubereitungen von chinoloncarbonsaeuren |
| JPS63188626A (ja) * | 1987-01-30 | 1988-08-04 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸の可溶化方法 |
| DE3902079A1 (de) * | 1988-04-15 | 1989-10-26 | Bayer Ag | I.m. injektionsformen von gyrase-inhibitoren |
| EP0507851B1 (en) * | 1989-12-29 | 1997-04-02 | Abbott Laboratories | Quinolone carboxylic acid--metal ion--acid complexes |
| US5084276A (en) * | 1990-01-05 | 1992-01-28 | Abbott Laboratories | Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation |
| EP0443381B2 (en) * | 1990-02-14 | 1997-10-22 | Takeda Chemical Industries, Ltd. | Effervescent composition, its production and use |
| FR2665635A1 (fr) * | 1990-08-10 | 1992-02-14 | Merck Sharp & Dohme | Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation. |
| US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
| US5235054A (en) * | 1992-07-15 | 1993-08-10 | Pfizer Inc. | 3-carboxaldehyde substituted quinolines and naphthyridines |
| JPH0782141A (ja) * | 1993-09-17 | 1995-03-28 | Tanabe Seiyaku Co Ltd | 動物用注射剤 |
-
1996
- 1996-11-13 CN CN96199249A patent/CN1104899C/zh not_active Expired - Lifetime
- 1996-11-13 DK DK96935251T patent/DK0868183T3/da active
- 1996-11-13 JP JP52344797A patent/JP3416145B2/ja not_active Expired - Lifetime
- 1996-11-13 NZ NZ320545A patent/NZ320545A/xx not_active IP Right Cessation
- 1996-11-13 SK SK807-98A patent/SK284412B6/sk not_active IP Right Cessation
- 1996-11-13 EP EP96935251A patent/EP0868183B1/en not_active Expired - Lifetime
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 IL IL12445496A patent/IL124454A/xx not_active IP Right Cessation
- 1996-11-13 HU HU9903726A patent/HU227918B1/hu unknown
- 1996-11-13 ES ES96935251T patent/ES2167609T3/es not_active Expired - Lifetime
- 1996-11-13 SI SI9630422T patent/SI0868183T1/xx unknown
- 1996-11-13 BR BR9612230A patent/BR9612230A/pt active IP Right Grant
- 1996-11-13 CA CA002239352A patent/CA2239352C/en not_active Expired - Lifetime
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/en not_active Ceased
- 1996-11-13 AT AT96935251T patent/ATE212551T1/de active
- 1996-11-13 DE DE69618987T patent/DE69618987T2/de not_active Expired - Lifetime
- 1996-11-13 RU RU98111831A patent/RU2141827C1/ru active
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/cs not_active IP Right Cessation
- 1996-11-13 PT PT96935251T patent/PT868183E/pt unknown
- 1996-11-13 PL PL96328001A patent/PL186795B1/pl unknown
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/ko not_active Expired - Lifetime
- 1996-11-13 UA UA98063226A patent/UA56151C2/uk unknown
- 1996-11-15 TW TW085114021A patent/TW449475B/zh not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/es not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/xx active
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/fr unknown
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/fr active
- 1996-12-18 MA MA24427A patent/MA24035A1/fr unknown
- 1996-12-19 HR HR960607A patent/HRP960607B1/xx not_active IP Right Cessation
- 1996-12-19 GT GT199600098A patent/GT199600098A/es unknown
- 1996-12-19 AR ARP960105774A patent/AR005147A1/es active IP Right Grant
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-20 CO CO96066993A patent/CO4480098A1/es unknown
- 1996-12-20 RS YU69096A patent/RS49523B/sr unknown
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/xx unknown
-
1998
- 1998-05-25 IS IS4755A patent/IS2010B/is unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/bg unknown
- 1998-06-19 MX MX9805026A patent/MX9805026A/es unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4480098A1 (es) | Formulaciones de danofloxacina inyectable que comprenden un compuesto de cinc con un disolvente complementario . | |
| CY1118334T1 (el) | Χρηση δαπτομυκινης | |
| ES2073678T3 (es) | Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion. | |
| ES2084944T3 (es) | Amidas terapeuticas. | |
| BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
| FI914391A0 (fi) | Sammansaettningar vilka foerstaerker hudens permeabilitet. | |
| ES2074513T3 (es) | Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo. | |
| MX9301929A (es) | Derivados de pirimidina y procedimientos para su preparacion. | |
| ES2063033T3 (es) | Empleo de igf-ii en el tratamiento de la enfermedades de los huesos. | |
| ATE281171T1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
| BR9904150A (pt) | Composições de proteìnas estabilizadas | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| DK98089A (da) | Medikament-lipid-systemer med lav toxicitet | |
| EA200200995A1 (ru) | Применение композиций азалидных антибиотиков для лечения или предупреждения бактериальных или протозойных инфекций у млекопитающих | |
| ES2156980T3 (es) | Composiciones que tienen efectos fungitoxicos sinergicos. | |
| BR0009524A (pt) | Uso de um composto, e, composição farmacêutica ou veterinaria | |
| AR006523A1 (es) | Compuestos ciclicos, inhibidores de la adhesion | |
| BR0014826A (pt) | Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm | |
| ES2111163T3 (es) | Uso de fosfonatos para el tratamiento de la osteoporosis. | |
| ES2135342B1 (es) | Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama. | |
| SE8602743D0 (sv) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| CL2004000765A1 (es) | Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo. | |
| MX9304197A (es) | Nuevo uso de dimero de lisozina y composiciones que lo contienen. | |
| MX9400072A (es) | Agentes antiinflamatorios derivados de difluoropentapeptido. | |
| BR9714945A (pt) | Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos |